Free Trial

Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target

$25.59
0.00 (0.00%)
(As of 07/12/2024)

Deciphera Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 10 Wall Street analysts who have issued ratings for Deciphera Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a buy rating for DCPH.

Consensus Price Target

$24.17
-5.54% Downside
High Forecast$30.00
Average Forecast$24.17
Low Forecast$16.00

According to the 10 analysts' twelve-month price targets for Deciphera Pharmaceuticals, the average price target is $24.17. The highest price target for DCPH is $30.00, while the lowest price target for DCPH is $16.00. The average price target represents a forecasted downside of -5.54% from the current price of $25.59.

TypeCurrent Forecast
7/28/23 to 7/27/24
1 Month Ago
6/28/23 to 6/27/24
3 Months Ago
4/29/23 to 4/28/24
1 Year Ago
7/28/22 to 7/28/23
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$24.17$24.17$23.00$21.78
Forecasted Upside-5.54% Downside30.25% Upside69.74% Upside32.83% Upside
Get Deciphera Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

DCPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DCPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Deciphera Pharmaceuticals Stock vs. The Competition

TypeDeciphera PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.30
2.72
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-5.54% Downside3,123.40% Upside9.09% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/30/2024Guggenheim
3 of 5 stars
 Reiterated RatingBuy ➝ Neutral
4/30/2024JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Perform
4/30/2024Barclays
2 of 5 stars
 UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $26.00+2.85%
4/29/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/29/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$26.00 ➝ $25.60+1.55%
4/29/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$25.60+1.55%
3/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$14.00 ➝ $16.00+2.24%
2/7/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$22.00 ➝ $23.00+64.05%
10/31/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$25.00 ➝ $30.00+151.47%
10/30/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$18.00 ➝ $23.00+82.54%
2/7/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$28.00 ➝ $30.00+79.53%
1/25/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$25.00 ➝ $30.00+66.20%
8/29/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$25.00+68.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:01 AM ET.

DCPH Forecast - Frequently Asked Questions

What is Deciphera Pharmaceuticals' forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Deciphera Pharmaceuticals is $24.17, with a high forecast of $30.00 and a low forecast of $16.00.

Should I buy or sell Deciphera Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.

Does Deciphera Pharmaceuticals's stock price have much upside?

According to analysts, Deciphera Pharmaceuticals's stock has a predicted upside of 30.25% based on their 12-month stock forecasts.

Has Deciphera Pharmaceuticals been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Deciphera Pharmaceuticals's stock had 1 upgrade and 1 downgrade by analysts.

What analysts cover Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has been rated by research analysts at Barclays, Guggenheim, Jefferies Financial Group, JMP Securities, Jonestrading, and Leerink Partnrs in the past 90 days.

Do Wall Street analysts like Deciphera Pharmaceuticals more than its competitors?

Analysts like Deciphera Pharmaceuticals less than other "medical" companies. The consensus rating for Deciphera Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DCPH compares to other companies.


This page (NASDAQ:DCPH) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners